Sign In
25 Nov 2013 09:48
Press Release 25 November 2013
Cyprotex PLC
("Cyprotex" or "the Company")
Director dealing
25 November 2013- The Company received notification that John Dootson, Chief Financial Officer of the Company, transferred 12,289 Convertible Loan Notes to his wife. The Company issued £4 million of Convertible Loan Notes in the Company on 26 September 2013. Mr Dootson's beneficial interest in the Convertible Loan Notes remains unchanged.
Cyprotex PLC |
Tel : +44 (0)1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer | |
John Dootson, Chief Financial Officer | |
Mark Warburton, Chief Operating Officer and Legal Counsel | |
ir@cyprotex.com | www.cyprotex.com |
N + 1 Singer (NOMAD and broker to Cyprotex) | Tel : +44 (0)20 7496 3000 |
Shaun Dobson | |
shaun.dobson@n1singer.com | |
Jenny Wyllie | |
jenny.wyllie@n1singer.com | www.nplus1singer.com |
FTI Consulting | Tel : +44 (0)20 7831 3113 |
Simon Conway | |
Mo Noonan | |
cyprotex@fticonsulting.com | www.fticonsulting.com |
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotech's to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.
Follow the stocks
